Top Markets
Coin of the day
Chinook Therapeutics, Inc. Chinook Therapeutics, Inc.

Chinook Therapeutics, Inc.

KDNY
Rank in Stocks #7144
Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical... Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical development phase, is dedicated to the identification, progression, and market introduction of precise medical treatments for kidney-related conditions. The company's primary therapeutic candidate, atrasentan, is an endothelin receptor antagonist currently in Phase III clinical trials. This drug aims to treat IgA nephropathy and various other glomerular diseases characterized by proteinuria. Beyond its lead program, Chinook's investigational pipeline includes BION-1301, an anti-APRIL monoclonal antibody, which is presently being evaluated in a Phase I/II study for IgA nephropathy. Another promising candidate is CHK-336, an oral small molecule designed to inhibit LDHA, intended for patients with primary hyperoxaluria. The firm also maintains active research initiatives exploring solutions for other uncommon and severe chronic kidney ailments. Chinook Therapeutics, Inc. is based in Seattle, Washington.
Share Price
$40.39
Last synced: 2023-08-18
Market Cap
$1.70B
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Chinook Therapeutics, Inc. (KDNY)

Category

Stock price history for Chinook Therapeutics, Inc. (KDNY)
Highest end of day price: $40.34 on 2023-08-01

Lowest end of day price: $177.63 on 2015-04-01
Stock price history of Chinook Therapeutics, Inc. from 2015 to 2026
Annual Stock Price Performance
Year Performance
2023 63.66%
2022 55.54%
2021 0.37%
2020 175.05%
2019 -57.15%
2018 -67.16%
2017 -26.51%
2016 -62.61%
2015 0.00%
Stock price for similar companies or competitors
Company Stock price Change 1y% Country
$548.36 39.87%
US
$1.06K 50.29%
NL
$121.21 -12.72%
AU
$140.81 475.44%
US
$765.25 7.74%
CH